MarketBeat
10 Nov 2026, 06:13 UTC · 1d ago
Impact · against what's priced in
Celldex provides a concrete regulatory roadmap and financial runway, with the 2027 filing timeline and $650 million cash balance reducing execution risk. The upcoming atopic dermatitis data by year-end serves as a near-term valuation catalyst separate from the primary urticaria launch.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Celldex plans to submit a biologics license application for barzolvolimab in 2027 using full 52-week Phase 3 data.
Newreported at Guggenheim’s 3rd Annual Healthcare Innovation Conference
So whatThe filing timeline pushes the potential for commercial revenue to late 2027 or 2028.
More positive than 93% of claims this week
Phase 3 EMBARQ studies showed complete responses in a majority of patients and clearing of angioedema at 12 weeks.
Continue reading
5 related stories
The company's plan to submit a BLA in 2027 and its $650 million cash balance provide a clear path to launch without immediate dilutive financing. Additionally, the expectation of atopic dermatitis data by the end of the year creates a distinct catalyst ahead of the main regulatory filing.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inreferences initial data release mentioned in text
More positive than 85% of claims this week
The company holds $650 million in cash as of the third quarter.
Newreported as third-quarter cash balance
So whatExisting funds cover the runway through 2028, eliminating the need for dilutive financing before the initial launch.
More positive than 63% of claims this week
Celldex expects to release atopic dermatitis data by the end of the year.
Newguidance given at the conference
So whatPositive results before year-end would provide a second catalyst to support the valuation ahead of the 2027 filing.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
Positive Phase 3 data for barzolvolimab, strong cash position, and a clear regulatory timeline for BLA submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
10h ago
−2.1%
Price is moving against the score
$30.59 vs $31.24 close before publication (Nov 9) · not market-adjusted
CLDX chart →
